目的:观察t(8;21)急性髓系白血病(AML)的临床特征并分析影响预后的因素。方法:回顾性分析郑州大学第一附属医院68例初治成人t(8;21)AML患者的血常规、骨髓细胞形态学、免疫表型、细胞遗传学、疗效及生存状况,分析影响总体生存(OS)、无...目的:观察t(8;21)急性髓系白血病(AML)的临床特征并分析影响预后的因素。方法:回顾性分析郑州大学第一附属医院68例初治成人t(8;21)AML患者的血常规、骨髓细胞形态学、免疫表型、细胞遗传学、疗效及生存状况,分析影响总体生存(OS)、无复发生存(RFS)的因素。结果:68例t(8;21)AML按FAB分型1例为M1型,1例为M4型,66例为M2型。单纯t(8;21)AML病例占38.2%(26/68),伴附加染色体异常病例占61.8%(42/68),主要为伴性染色体(-Y或-X)缺失。59例行流式细胞术检测,CD34阳性率93.2%,CD19阳性率54.2%,CD56阳性率79.7%,CD34CD19共表达者占54.2%。总体完全缓解(CR)率为94.1%(64/68),1个疗程CR率为73.5%(50/68)。64例可统计生存的患者3 a OS率为44.8%,3 a RFS率为47.9%。白细胞指数、染色体核型、中大剂量Ara-C疗程数对OS有影响(P<0.05)。结论:白细胞指数、染色体核型、中大剂量Ara-C疗程数是影响t(8;21)AML预后的主要因素。展开更多
Objective:To find out how to overcome resistance during multiple myeloma(MM) treatment through establishing a multidrug resistant human multiple myeloma cell line and investigating its biological features.Methods:The ...Objective:To find out how to overcome resistance during multiple myeloma(MM) treatment through establishing a multidrug resistant human multiple myeloma cell line and investigating its biological features.Methods:The parent cell line MOLP-2 was exposed to different concentrations of melphalan and a melphalan-resistant cell line MOLP-2/R was identified by continuous stepwise selection.The cell morphology and growth curves were examined.Protein levels of P-gp, MRP and FANCD2 monoubiquitination were checked by Western blotting.The IC50 of melphalan and resistance index(RI) were detected by MTT assay.Results:A melphalan-resistant cell line MOLP-2/R was finally identified.The RI of MOLP-2/R cells to melphalan was 6.03.Besides melphalan it was cross resistant to other chemotherapeutic agents, including ADM, CTX, DDP and VP-16.The multiplication time was postponed(P < 0.05).Studies showed that FANCD2 protein monoubiquitination was enhanced, but the levels of P-gp and MRP expressions in the MOLP-2/R cells were similar with the parent cells.Conclusion:MOLP-2/R cell line may serve as an ideal model for exploring the mechanism of MDR.Over-expression of FANCD2 protein monoubiquitination might contribute to acquired drug resistance in MOLP-2/R cell line.展开更多
文摘目的:观察t(8;21)急性髓系白血病(AML)的临床特征并分析影响预后的因素。方法:回顾性分析郑州大学第一附属医院68例初治成人t(8;21)AML患者的血常规、骨髓细胞形态学、免疫表型、细胞遗传学、疗效及生存状况,分析影响总体生存(OS)、无复发生存(RFS)的因素。结果:68例t(8;21)AML按FAB分型1例为M1型,1例为M4型,66例为M2型。单纯t(8;21)AML病例占38.2%(26/68),伴附加染色体异常病例占61.8%(42/68),主要为伴性染色体(-Y或-X)缺失。59例行流式细胞术检测,CD34阳性率93.2%,CD19阳性率54.2%,CD56阳性率79.7%,CD34CD19共表达者占54.2%。总体完全缓解(CR)率为94.1%(64/68),1个疗程CR率为73.5%(50/68)。64例可统计生存的患者3 a OS率为44.8%,3 a RFS率为47.9%。白细胞指数、染色体核型、中大剂量Ara-C疗程数对OS有影响(P<0.05)。结论:白细胞指数、染色体核型、中大剂量Ara-C疗程数是影响t(8;21)AML预后的主要因素。
文摘Objective:To find out how to overcome resistance during multiple myeloma(MM) treatment through establishing a multidrug resistant human multiple myeloma cell line and investigating its biological features.Methods:The parent cell line MOLP-2 was exposed to different concentrations of melphalan and a melphalan-resistant cell line MOLP-2/R was identified by continuous stepwise selection.The cell morphology and growth curves were examined.Protein levels of P-gp, MRP and FANCD2 monoubiquitination were checked by Western blotting.The IC50 of melphalan and resistance index(RI) were detected by MTT assay.Results:A melphalan-resistant cell line MOLP-2/R was finally identified.The RI of MOLP-2/R cells to melphalan was 6.03.Besides melphalan it was cross resistant to other chemotherapeutic agents, including ADM, CTX, DDP and VP-16.The multiplication time was postponed(P < 0.05).Studies showed that FANCD2 protein monoubiquitination was enhanced, but the levels of P-gp and MRP expressions in the MOLP-2/R cells were similar with the parent cells.Conclusion:MOLP-2/R cell line may serve as an ideal model for exploring the mechanism of MDR.Over-expression of FANCD2 protein monoubiquitination might contribute to acquired drug resistance in MOLP-2/R cell line.